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E-mail address: J.Leemans@student.ulg.ac.be (J. LeKnowledge about the use of inhaled bronchodilators in cats with so-called ‘feline asthma’ is limited and
relies on the experience of clinicians treating these patients. A randomised controlled four-way crossover
study was therefore designed to compare the effects of salbutamol (SAL, 100 lg), ipratropium bromide
(IB, 20 lg) and a combination of both (SAL/IB, 100 lg/20 lg), delivered through a pressurised metered-
dose inhaler (pMDI) connected to a spacing chamber, on allergen-induced bronchospasms in ﬁve Ascaris
suum (AS)-sensitised cats. Four AS bronchial provocation challenges were carried out at 1 week intervals,
followed by one of four treatment protocols: SAL, IB, SAL/IB or control (untreated). Enhanced pause
(Penh), an estimator of airﬂow limitation measured by barometric whole-body plethysmography, was
repeatedly assessed within 120 min following the administration of each treatment protocol. Responses
to inhaled medications were evaluated by calculating the area under the time–response curves (AUC)
from 0 to 60 or 120 min after drug administration (AUC0–60, AUC0–120), as well as the times required
for half-recovery (T50%) or for returning to nearly basal conditions (T20%).
No signiﬁcant differences were found among the four study groups, with reference to the mean AUC0–
60, T20% and T50% values of Penh (P > 0.05). Mean AUC0–120 values of Penh were similar between the bron-
chodilators tested, but were signiﬁcantly lower than those in the untreated group. It was concluded that
inhalation of SAL, IB and SAL/IB via pMDI failed to improve most Penh-derived parameters, which sug-
gested that these bronchodilators were of limited efﬁcacy in reversing allergen-induced bronchospasm
in cats. However, further studies using a larger number of animals are warranted to investigate if differ-
ent drugs or delivery devices or higher dosages may be more effective.
 2009 Elsevier Ltd. All rights reserved.Introduction
Feline allergic asthma is a chronic inﬂammatory disorder within
the lower respiratory tract that is commonly encountered in pet
cats. Clinical signs include chronic coughing, wheezing and
intermittent respiratory distress. These symptoms arise from
obstruction of the lower airways caused by airway wall oedema,
excessive mucus secretion, inﬂammatory cellular inﬁltrates and
reversible airway smooth-muscle constriction in response to spe-
ciﬁc aeroallergens (Padrid, 2000; Hirt, 2005). Non-allergic stimuli
(dust litter, smoke or stress) have been hypothesised to trigger
bronchoconstriction in a non-speciﬁc manner. Because the clinical
signs observed in feline asthma are at least partly due to reversible
airway smooth-muscle constriction, bronchodilator therapy
should be effective for symptomatic relief of acute respiratory
distress.ll rights reserved.
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emans).Because cats spontaneously show allergic asthma, particular
emphasis has been placed on developing feline models of allergic
asthma to further explore the pathogenesis of the human condi-
tion. On the basis of sensitisation to experimental (Ascaris suum)
or clinically relevant allergens (Bermuda grass, house-dust mite),
these models successfully mimicked many hallmark features of
both feline and human diseases: eosinophilic airway inﬂammation,
reversible airﬂow limitation subsequent to inhalation of speciﬁc
allergens, non-speciﬁc bronchial hyperresponsiveness and airway
remodelling (permanent structural changes within airways) at ad-
vanced stages (Padrid et al., 1995; Norris Reinero et al., 2004; Kirs-
chvink et al., 2007).
More interestingly, biphasic increases in lung resistance were
evidenced in A. suum (AS)-sensitised cats, with the following pro-
ﬁle: one peak within 10 min following allergen exposure, a subse-
quent return to baseline in most cats, and a second peak after 24 h
(Padrid et al., 1995). Although any extrapolation between species
should be considered with caution, this peculiar pattern of changes
in pulmonary function strikingly evokes the allergen-induced dual
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asthmatics. The early asthmatic reaction (EAR) to inhaled allergen
results from IgE-mediated degranulation of mast cells, which re-
lease bronchospastic mediators (histamine, eicosanoids), the late
asthmatic reaction (LAR) involves the recruitment and activation
of eosinophils, CD4+ T cells, basophils, neutrophils and macro-
phages (Bousquet et al., 2000). However, to the best of our knowl-
edge, no study has been speciﬁcally designed to assess the
reproducibility of asthmatic reactions following successive aller-
gen challenges, which is critical for the accurate screening of bron-
chodilating drugs.
Development and implementation of feline asthmamodels with
standardised allergen exposures (type, duration, quantity and tim-
ing) has greatly facilitated the search for targeting novel therapies
in cats and, to a lesser extent, in human beings. Historically, cyclo-
sporine A, an effective inhibitor of T-cell activation, has been the
ﬁrst drug to be shown to prevent bronchial hyperreactivity and
cytological/morphological alterations in the airways of AS-sensi-
tised and chronically challenged cats (Padrid et al., 1996). Potent
immunosuppressive effects, requirement for continued monitoring
and exorbitant expenses have precluded cyclosporine A from the
routine management of feline asthma and emphasise the need to
widen therapeutic options. In two randomised controlled trials
on cats with experimental asthma, inhaled corticosteroids, either
as monotherapy or in combination with long-acting b2-adrenergic
agonists, were reported to display approximately similar efﬁcacy
than oral corticosteroids in reducing eosinophilic airway inﬂam-
mation, thereby representing a valuable alternative for the clinical
condition (Reinero et al., 2005; Leemans et al., 2008). Treatments
directed towards speciﬁc effector systems are unsatisfactory
because cyproheptadine (a serotonin antagonist) at low or high
doses, cetirizine (a 2nd-generation selective histamine-receptor
antagonist) and zaﬁrlukast (cysteinyl leukotriene-1-receptor
antagonist) failed to dampen eosinophilic airway inﬂammation in
experimentally asthmatic cats (Reinero et al., 2005; Schooley
et al., 2007). In contrast, allergen-speciﬁc immunotherapy, which
is a curative desensitising therapy for allergic diseases, increasingly
promises to be a new approach for feline asthma, although it re-
mains experimental at this stage (Reinero et al., 2006, 2008; Lee-
Fowler et al., 2009). Considering the above concerns, randomised
controlled studies that assess the palliative use of bronchodilators
in experimentally asthmatic cats with acute airway obstruction are
still lacking.
Aerosol therapy offers the advantages of achieving higher con-
centrations of medications in target tissues while simultaneously
attenuating their systemic toxicity (Boothe, 2004). In feline medi-
cine, pulmonary drug delivery may be accomplished either by neb-
ulisers or a human pressurised metered-dose inhaler (pMDI),
adapted to animal use by connecting a spacing chamber and a face-
mask. Recently, a pilot study conducted on healthy cats with carba-
chol-induced bronchoconstriction addressed both magnitude and
duration of the antispasmodic effects of b2-sympathomimetic
and anticholinergic agents administered by pMDI and/or nebulisa-
tion (Leemans et al., 2009). It is worthwhile to mention that both
methods of delivery lead to a similar degree of bronchoprotection
at the doses studied. Moreover, concurrent exposure to salbutamol
(SAL) (b2-agonist) and ipratropium bromide (IB) (anticholinergic
agent) delivered by pMDI was found to generate a highly synergis-
tic interaction. At unknown doses and with unspeciﬁed onsets of
action, SAL administered through pMDI appeared to reverse airway
obstruction in cats diagnosed with asthma (Rozanski and Hoffman,
1999). Although preliminary data suggested that these drugs may
be useful for at-home management of asthmatic cats, bronchodila-
tors delivered by pMDI should be studied more closely, especially
with reference to anticholinergic drugs, drug interactions, dosages
and temporal effects on lung function.Methods for evaluating the response of bronchodilators over
time in cats with allergen-induced EAR include the follow-up of
airﬂow limitation by pulmonary function testing. Barometric
whole-body plethysmography (BWBP) has been validated as a
non-invasive pulmonary function test for repeated assessments
of the respiratory system in un-sedated, unrestrained and sponta-
neously breathing cats (Kirschvink et al., 2006). Through calcula-
tion of the enhanced pause (Penh), a unitless index of airﬂow
limitation correlated with pulmonary resistance (Hamelmann
et al., 1997; Halloy et al., 2004; Kirschvink et al., 2005; Hirt et al.,
2008), BWBP has allowed the quantiﬁcation of both airway
obstruction and its reversal with a b2-agonist in cats with naturally
developing asthma (Rozanski and Hoffman, 1999).
Using BWBP, the aims of this study were as follows: ﬁrst, to test
the reproducibility of allergen-induced EAR in high-responsive cats
sensitised to AS; second, to compare, on the basis of a randomised
controlled four-way crossover trial, the effects of SAL (100 lg), IB
(20 lg) and a combination of both (SAL/IB: 100 lg/20 lg), deliv-
ered by pMDI, on allergen-induced bronchospasms in AS-sensi-
tised cats. The authors hypothesised that inhaled SAL and IB
would be effective as monotherapies in reversing early allergen-
elicited bronchospasm and that combining them would enhance
their efﬁcacy in a synergistic fashion.Material and methods
Animals
Eight shorthaired AS-sensitised cats, aged 41 months (Harlan Netherlands; four
neutered males, four neutered females; mean bodyweight [BW]: 4.7 ± 0.3 kg), were
recruited from a colony of cats experimentally sensitised to AS (Kirschvink et al.,
2007). The selected cats were between 11 and 29 months of age at initial sensitisat-
ion, had a range of 3–8 AS-challenges in previous studies, and all had their last AS-
challenge 9 months previously. They had no history of respiratory tract infection
within a period of 6 weeks before being entered in the study. To be eligible, the cats
had to demonstrate at least two of the following features of the asthma phenotype
after AS stimulation: an increase in total cellular count of the bronchoalveolar la-
vage ﬂuid (BALF) to >300 cells/lL; an increase in percentage of BALF eosinophils
to >18% (Padrid et al., 1991; Hawkins et al., 1994) and/or demonstrable bronchial
hyperreactivity to carbachol (deﬁned as a decrease in C-Penh300 after AS-challenge
compared with saline-challenge) (Table 1). These data were retrieved from previous
research conducted by the same investigators to maximally respect the welfare of
the tested animals.
The enrolled animals were housed and cared for according to the national
guidelines and the principles proposed by the European Council for the Care of Lab-
oratory Animals. Each cat was weighed at weekly intervals.Study design
First, airway responsiveness towards inhaled carbachol, which is a non-invasive
indicator of lower airway inﬂammation and bronchial responsiveness to non-aller-
gic stimuli, was assessed in the selected cats by BWBP (Leemans et al., 2009). Sub-
sequently, the subjects had to successfully complete a 2 week initial inhalation
challenge-test period before enrolment in a therapeutic trial based on a randomised
controlled four-way crossover design (Fig. 1).
The initial inhalation challenge-test period was carefully designed (1) to screen
for an AS-induced EAR among the eight selected subjects and (2) to test the repeat-
ability of AS-related changes in Penh after two consecutive allergen exposures. The
screening period consisted of three successive inhalation challenges as follows:
sterile saline (0.9% NaCl) (Pre-challenge) and saline solutions containing incremen-
tal concentrations of AS allergen (Greer Laboratories) (Challenges 1 and 2), respec-
tively, conducted at 1 week intervals. At each time point, the cats underwent
repeated pulmonary function tests performed by BWBP. Of the eight subjects
screened, ﬁve (Table 1; Nos. 3, 4, 6, 7 and 8) fulﬁlled the eligibility criteria (refer
‘Initial inhalation challenge-test period’) for entry into the following crossover trial.
The therapeutic trial started at the end of a 2-week washout period. This was a
randomised, controlled, single-dose, four-way crossover study aimed at investigat-
ing the effects of inhaled bronchodilators delivered by pMDI. On four different
study days, the enrolled cats were exposed to the AS allergen. Shortly after the ini-
tiation of allergen-induced EAR, they randomly received inhaled SAL (100 lg, 1
puff); inhaled IB (20 lg, 1 puff); a randomised combination of SAL/IB (100 lg/
20 lg, each 1 puff); or no drug. The cats were crossed over to the other treatments
at 1 week intervals, so that each cat received all four treatments during the study.
Table 1
Cytology of the bronchoalveolar lavage ﬂuid and carbachol concentrations increasing Penh to 300% of baseline, previously determined in recruited cats after saline and Ascaris
suum challenges.
Cat Gender Time points Total cells (cells/lL BALF) Eosinophils (%) C-Penh300 % (g/100 mL)
1 M Saline 165 7 0.017
A. suum 340 60 0.010
2 F Saline 205 1.5 0.031
A. suum 316 51.5 0.018
3 F Saline 260 2.5 0.035
A. suum 736 60 0.045
4 F Saline 245 13 0.050
A. suum 457 46 0.044
5 M Saline 67.5 2 0.010
A. suum 336 68 0.009
6 M Saline 109 5 0.021
A. suum 84 67 0.011
7 F Saline 92.5 5 0.020
A. suum 637 18.5 0.019
8 M Saline 117 7 0.035
A. suum 109 55 0.018
BALF, bronchoalveolar lavage ﬂuid; C-Penh300, index of non-speciﬁc bronchial responsiveness – carbachol concentration increasing Penh to 300% of baseline. Of the ﬁrst eight
recruited cats, ﬁve (Nos. 3, 4, 6, 7 and 8) fulﬁlled the eligibility criteria for entrance into the comparative bronchodilator trial.
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Fig. 1. Study design. AS, Ascaris suum; PRE, CH1 and CH2, placebo challenge, ﬁrst and second A. suum challenges, respectively, carried out during the initial inhalation
challenge-test period; T1–T4, successive periods for assessment of treatment efﬁcacy; BWBP, barometric whole-body plethysmography; ART, airway responsiveness test.
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Liège.Initial inhalation challenge-test period
Two baseline recordings of the respiratory variables were carried out on cats
both at rest and after a 1 min saline nebulisation with a nebuliser (Ultraneb Devil-
biss 2000, Devilbiss Healthcare) in the BWB plethysmograph. Cats then underwent
either a single 5 min aerosol exposure with sterile saline (Pre-challenge) or succes-
sive 5 min challenges with increasing AS concentrations (0.005%, 0.01%, 0.02%,
0.04% and 0.08%) (Challenge 1). The challenges of saline and AS were followed bya 5 min session of BWBP. The AS inhalations were stopped after the occurrence of
a sustained dyspnoea, concurrent with Penh values exceeding 300% of post-saline
baseline measurements (EAR) or after the maximum dose was reached. Respiratory
parameters were assessed at 5, 15, 30, 45, 60, 80, 100, 120, 150, 180, 210 and
240 min after recording the placebo challenge (Pre-challenge) or the last dose of
AS (Challenge 1).
For each responsive animal (Table 1; Nos. 3, 4, 6, 7 and 8), a second AS bronchial
provocation test (Challenge 2) was carried out by administering the same incre-
mental doses of allergen as in Challenge 1 to test the repeatability of AS-related
changes in Penh. If repeatable, the incremental doses of allergen leading up to
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Fig. 2. Penh values recorded in an unresponsive cat (No. 2) after two baseline
recording periods and successive challenges with doubling concentrations of Ascaris
suum allergen. Penh, enhanced pause; Basal and 0.9% NaCl, Penh values recorded,
respectively, at rest and following 1 min nebulisation with sterile saline; Log2 (AS):
log2-transformed concentrations of aerosolised A. suum allergen.
J. Leemans et al. / The Veterinary Journal 186 (2010) 76–83 79Therapeutic trial
On each study day, cats were challenged with aerosolised AS allergen. When
measurements of AS-triggered EAR had been completed, the drugs were delivered
to cats and each animal then tested. The functional response to inhaled bronchod-
ilators was investigated at 5, 15, 30, 45, 60, 80, 100 and 120 min after administra-
tion. The AS bronchial provocation tests were otherwise similar in design to the
initial inhalation challenge-test period (i.e. two baseline recordings with the same
provocative doses of allergen and 5 min sessions of BWBP).
A. suum or placebo challenges
A. suum or saline solutions were aerosolised using an ultrasonic nebuliser
(Ultraneb Devilbiss 2000, Devilbiss Healthcare) known to generate particles with
diameters ranging from 0.5 to 5 lm. The aerosol output was set at 3 mL/min. A ﬁxed
airﬂow through the nebuliser propelled the aerosolised particles into an animal
chamber (height: 30 cm; length: 37.5 cm; width: 28.5 cm) through a single lateral
inlet (30 mm diameter). Upper outlets (5 mm diameter) allowed the safe evacua-
tion of aerosol by an extractor hood.
Drug administration
Inhaled SAL, IB and SAL/IB were administered to AS-challenged cats using a
pMDI and a spacing chamber connected to a facemask (Aerokat, Trudell Medical)
immediately after recording the lung function in response to the last allergen expo-
sure. The facemask was carefully applied on the cat’s nose and mouth and the pMDI
was activated once and the facemask was then held in place until the animal had
taken 10 deep breaths. To avoid cross-contamination between SAL and IB, two dif-
ferent spacing chambers and facemasks were used. For the combination SAL/IB, the
cats took 10 deep breaths before the second drug was delivered. Using a 3:2 alloca-
tion ratio, cats were randomised to one of the two different treatment sequences
(sequence 1: SAL/IB; sequence 2: IB/SAL). Compliance with inhalation therapy
was assessed by counting the number of failed and successful drug administrations
on the basis of previous delivery procedures.
Barometric whole-body plethysmography
Data acquisition of respiratory parameters was conducted using BWBP for unre-
strained conscious animals. The system adapted for cats was as previously de-
scribed (Hoffman et al., 1999; Hirt et al., 2003; Kirschvink et al., 2006). Brieﬂy,
the cats were placed in the transparent Plexiglas main chamber of the BWB plethys-
mograph (Buxco Electronics, height: 25 cm; length: 51 cm; width: 30 cm), venti-
lated by a continuous bias ﬂow (Air Control Industries) adjusted to a ﬂow rate of
4 L/min by a ﬂow meter (Inﬂux, Cache Instrumentation). The inlet, through a screen
pneumotachograph (35 mm diameter), and outlet for air were at the opposite ends
of the chamber. Two sensor probes within the animal chamber continuously mon-
itored the temperature and humidity. A differential pressure transducer (Buxco
Electronics) sampled pressure signals at 100 Hz, which were analysed on a
breath-by-breath basis by a BioSystem XA software (Buxco Electronics).
The following respiratory variables were recorded: respiratory frequency (f)
(cycles/min), inspiratory and expiratory times (Ti and Te) (ms), relaxation time
(RT, i.e. the time point when 65% of tidal volume is expired) (ms), peak inspiratory
and expiratory pseudoﬂows (PIF and PEF) (mL/s), estimated tidal volume (VT) (mL)
and estimated minute volume (MV: tidal volume  respiratory frequency) (mL).
The enhanced pause was calculated using the formula: Penh = ((Te  RT)/
RT  PEF/PIF). Waveforms disturbed by snifﬁng, vocalisations and body movements
were automatically excluded by the software when VT < 10 mL, Ti < 150 ms, Ti > 10
000 ms or when the difference between the inspiratory and expiratory volumes was
>20%.
Data analyses
The primary outcome was the functional response (evaluated using Penh) to AS
exposure and inhaled medications. Data were expressed as the arithmetic
mean ± standard error of the mean (SEM). Statistic analysis system (SAS 9.1, SAS
Institute) was used for the statistical analysis. For all analyses, differences were con-
sidered as signiﬁcant when P < 0.05.
For the initial inhalation challenge-test period, absolute Penh values were ana-
lysed by a mixed linear model to assess challenge effects (Pre-challenge, Challenges
1 and 2), changes over time and challenge by time interaction. If a signiﬁcant
challenge by time interaction was detected, further analyses for the individual chal-
lenges and time points were carried out.
For the therapeutic trial, Penh data were transformed before subsequent
calculations and statistical analyses, and were expressed as the per cent ratio of
the difference between the post-saline (NaCl) and bronchodilator treatment (time
x) values to the difference between the post-saline and EAR trigger values:
%DPenh ¼ Penh ðat time xÞ  Penh ðfollowing NaClÞ
Penh ðat EARÞ  Penh ðfollowing NaClÞ  100The response to inhaled bronchodilators was ﬁrst evaluated by the area under
the time–response curve from 0 min (i.e. the time at which cats were treated) to
60 min (AUC0–60) and 120 min (AUC0–120) following drug administration. Both
AUC0–60 and AUC0–120 were computed by trapezoidal integration. The AUC approach
is a useful means to assess the overall effect of inhaled medications over a predeter-
mined period of time (or several periods of time). Then, the times for studied
parameters to achieve exactly 50% (T50%) and 20% (T20%) of the post-challenge values
(at EAR) were calculated by linear interpolation of the time–response curves after
log-transformation of time data. The durations required for half-recovery (T50%) or
for returning to nearly basal conditions (T20%) provide additional information
regarding whether spontaneous resolution from EAR might be accelerated by the
interventional administration of an inhaled bronchodilator. AUC0–60, AUC0–120,
T20% and T50% values were compared between the treatment groups by one-way re-
peated measures ANOVA with post-hoc Fischer’s least signiﬁcant difference tests.Results
Initial inhalation challenge-test period
Of the eight subjects recruited in the initial inhalation chal-
lenge-test period, three were excluded from data analysis (Table
1; Nos. 1, 2 and 5) because they did not develop an EAR after stim-
ulation with ﬁve doubling concentrations of the AS allergen
(Fig. 2). Allergen related-changes in Penh of responsive cats are de-
picted in Fig. 3.
Over the 4 h recording period, signiﬁcant changes in Penh were
found between the Pre-challenge and Challenges 1 and 2 groups. A
signiﬁcant challenge by time interaction (P < 0.0001) was detected,
suggesting that responses to the placebo and AS-challenges dif-
fered over time. For the Pre-challenge group, pair-wise compari-
sons between post-saline and any other individual time points
were not signiﬁcant. For both Challenges 1 and 2 groups, Penh
was maximal after initiation of the allergen-induced EAR, and then
gradually resumed its respective post-saline values. Penh measure-
ments recorded after occurrence of the EAR signiﬁcantly exceeded
the post-saline values up to time point 60 min. Clinically, AS-stim-
ulated cats exhibited moderate to severe signs compatible with
bronchoconstriction, such as tachypnoea (70 cycles/min), expira-
tory dyspnoea, sporadic cough, increased and/or abnormal breath
sounds on lung auscultation (wheezes, crackles) and sometimes
reluctance to move. These clinical signs broadly paralleled the
time course of changes in lung function. At Challenge 1, two cats
(Table 1; Nos. 3 and 4) experienced an AS-induced LAR that was
evidenced by a signiﬁcant increase in Penh at 240 min and accom-
panying clinical signs of tachypnoea, moderate dyspnoea as well as
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Fig. 3. Time course of mean values of Penh obtained in Ascaris suum-sensitised cats
at baseline (Basal), after 1 min saline nebulisation (0.9% NaCl) and following a single
challenge with a placebo (Pre-challenge) or two successive challenges with A. suum
allergen (Challenges 1 and 2) (n = 5). EAR, allergen-triggered early asthmatic
reaction. Data shown are the mean values ± SEM. *Signiﬁcantly different from
Challenges 1 and 2, P < 0.05. §Signiﬁcantly different from Pre-challenge and





























Fig. 4. Time course of mean values of %DPenh obtained in Ascaris suum-sensitised
cats at baseline (Basal), after allergen-triggered early asthmatic reaction (EAR) and
5, 15, 30, 45, 60, 80, 100 and 120 min following inhalation of salbutamol (100 lg),
ipratropium bromide (20 lg) or a combination of both (100 lg/20 lg) through a
pressurised metered-dose inhaler (n = 5). Penh data are expressed as per cent ratio
of the difference between the post-saline (NaCl) and bronchodilator treatment
(time x) values to the difference between the post-saline and EAR trigger values
(%DPenh), and are shown as mean values with SEM.
80 J. Leemans et al. / The Veterinary Journal 186 (2010) 76–83When evaluating individual time points, pair-wise comparisons
between challenges did not reveal any signiﬁcant differences at
rest (basal) and following 1 min saline nebulisation (0.9% NaCl).
Compared to Pre-challenge, Penh values assessed during Chal-
lenges 1 and 2 were signiﬁcantly increased from the EAR trigger
(EAR) up to 60 min but they did not differ among themselves.
The LAR reported during Challenge 1 led to signiﬁcant increases
in Penh values at 240 min as compared with the Pre-challenge
and Challenge 2 groups.
Considering the spontaneous recovery from EAR within 80–
120 min and the confounding effects of inconsistent LAR, the mea-
surement period was shortened to 120 min for the therapeutic
trial.Therapeutic trial
No adverse reactions were reported after bronchodilator intake.
Compliance, previously deﬁned as the percentage of successful
bronchodilator intake, was >93% at the end of the study. Indeed,
one cat did not complete more than four deep breaths followingSAL administration, but data from this subject were not censored.
Preliminary statistical analysis on the absolute Penh values ob-
tained at baseline and after saline nebulisation did not show any
signiﬁcant differences among all four treatment groups (SAL, IB,
SAL/IB, untreated). Notably, the functional response to allergen
exposure (at EAR) was of similar degree among the four study
groups (P > 0.05).
Time-related bronchodilating effects of SAL (100 lg), IB (20 lg)
and SAL/IB (100 lg/20 lg) are depicted in Fig. 4. No signiﬁcant dif-
ferences were found among the four study groups, with reference
to the mean AUC0–60, T20% and T50% values of %DPenh. Mean
AUC0–120 values of %DPenh were similar between the tested bron-
chodilators, but signiﬁcantly lower than those calculated in the
untreated group (Table 2).Discussion
There is increasing recognition that feline asthma models are
needed to properly assess novel therapies for the clinical disease.
However, little is known whether successive allergen challenges
induce repeatable changes in lung function. In this study, we ﬁrst
conﬁrmed the reproducibility of two consecutive allergenic stimu-
lations as a prerequisite for the subsequent evaluation of bron-
chodilators according to a crossover design. Mainstay therapy for
feline asthma traditionally relies on corticosteroids to dampen
the underlying airway inﬂammation and on bronchodilators to
counter the acute airﬂow limitation. Although bronchodilators
delivered by pMDI are empirically used in feline asthmatic pa-
tients, their efﬁcacy, duration and onset of action, in addition to
their optimal dosage, have yet to be quantitatively assessed. The
technique of BWBP was used to address some of these issues in
the current study. Under the experimental conditions, neither the
single-drug treatments (SAL, IB) nor the combined medication
(SAL/IB) signiﬁcantly reduced the times for recovery (T50%, T20%)
and the allergen-elicited changes in Penh averaged over the ﬁrst
60 min after administration (AUC0–60). Among the Penh-derived
parameters, SAL and IB as monotherapies signiﬁcantly affected
AUC0–120, without additional beneﬁt when combining them.
Two successive allergen provocation tests carried out on ac-
tively sensitised cats triggered repeatable EAR peaking within the
ﬁrst minute after AS exposure, which spontaneously resolved
80 min later. Consistent with these ﬁndings, a substantial increase
in lung resistance was previously recorded in anesthetised AS-sen-
sitised cats within 10 min following acute allergen exposure, but
was not observed 90 min later (Padrid et al., 1995). Not only has
the feline asthma model based on AS sensitisation successfully
mimicked a fundamental feature of the asthma phenotype, namely
an immediate and reversible bronchoconstriction after allergen
exposure, but it has also pinpointed the progressive time-related
recovery from EAR within the current experimental framework.
In this context, computing the AUC of the plotted data against time
is a simple and valuable method to correct for this unavoidable
confounding factor when assessing bronchodilator efﬁcacy.
Viewed from a clinical perspective, the spontaneous resolution
from EAR raises concerns about how useful inhaled bronchodila-
tors would be in relieving acute bronchospasm in cats with
naturally developing asthma. Therefore, attempts were made to
assess whether this spontaneous resolution rate might be
accelerated by the interventional administration of an inhaled
bronchodilator. Determining the delay after which time cats with
allergen-induced bronchoconstriction return to nearly basal condi-
tions (T20%) is a complementary approach to AUC calculations for
evaluating bronchodilator effects, while accounting for the bias
due to spontaneous recovery.
Table 2
Mean values of area under the time–response curves from 0 min to 60 min and 120 min (AUC0–60, AUC0–120) after drug administration and times to achieve 50% and 20% of the
post-challenge values (T50% and T20%) calculated from Penh data recorded in Ascaris suum-sensitised and challenged cats either untreated or following inhalation of salbutamol
(100 lg), ipratropium bromide (20 lg) or a combination of both (100 lg/20 lg) through a pressurised metered-dose inhaler (n = 5).
Parameters Untreated SAL through pMDI (100 lg) IB through pMDI (20 lg) SAL/IB through pMDI (100 lg/20 lg) P
%DPenh
AUC0–60 3021 ± 638 1904 ± 235 1693 ± 172 1949 ± 638 0.063
AUC0–120 3879 ± 817a 2164 ± 228b 1974 ± 324b 2016 ± 817b 0.039
T20% (min) 63.2 ± 9.5 38.8 ± 5.5 39.1 ± 5.4 42.0 ± 7.2 0.079
T50% (min) 25.7 ± 8.8 9.5 ± 2.9 10.0 ± 2.4 11.9 ± 2.3 0.065
SAL, salbutamol; IB, ipratropium bromide; SAL/IB, combination of SAL and IB; pMDI, pressurised metered-dose inhaler; %DPenh, Penh expressed as per cent ratio of the
difference between the post-saline (NaCl) and bronchodilator treatment (time x) values to the difference between the post-saline and EAR trigger values; AUC0–60 and AUC0–
120, area under the time–response curves from 0 min to 60 min and 120 min, respectively, after drug administration; T50% and T20%, times to achieve 50% and 20%, respectively,
of the post-challenge values.
Data shown are the mean values ± SEM. NS, not signiﬁcant.
a,bData with different superscripts are signiﬁcantly different, P < 0.05.
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expected to trigger an EAR in the ﬁrst eight recruited AS-sensitised
cats. Although the number of responding animals appeared to be
related to the concentrations of challenging allergen, acute bron-
chospasm was not observed in all the sensitised cats even at the
highest concentrations (5/8 responders; 63%). Other investigators
have previously established an EAR occurrence of approximately
60% in human asthmatics undergoing an environmental challenge,
during which low amounts of allergen particles dispersed in the
ambient air are inhaled continuously over a long period of time
(Arvidsson et al., 2007). In spite of the presumed remarkable differ-
ences in deposition of allergen within the airways, the experimen-
tal challenge undertaken in this study reﬂected the asthmatic
response under normal environmental conditions well. Because
allergen-induced eosinophilic airway inﬂammation has been pre-
viously demonstrated in unresponsive cats (Table 1; Nos. 1, 2
and 5), it should be borne in mind that the lack of functional evi-
dence for an EAR does not preclude the subsequent development
of a delayed pulmonary inﬂammatory response (LAR), which is of
clinical importance. Finally, the reproducibility of LAR may be
questionable, because some responsive cats (Table 1; Nos. 3 and
4) showed inconsistent LAR between Challenges 1 and 2. It is con-
ceivable that both these cats responded well beyond the last time
point assessed (240 min) for Challenge 2, paralleling the case of
human beings in whom the onset of LAR is quite variable,
occurring as early as 3 h or as late as 8 h after exposure to allergen
(O’Byrne et al., 1987).
Neither incremental doses of inhaled allergen nor 12 consecu-
tive challenges with ﬁxed doses of aeroallergen (Norris Reinero
et al., 2004) proved to be sufﬁcient to elicit an EAR in research cats
with experimental asthma. Thus, factors other than the intensity of
allergen exposure during challenge appear to impact the occur-
rence and magnitude of allergen-induced EAR. The level of allergic
sensitisation (i.e. the circulating level of allergen-speciﬁc IgE) and
the degree of underlying bronchial hyperresponsiveness to non-
allergic stimuli, such as histamine and methacholine, are believed
to be crucial determinants of airway responsiveness to allergen
(Cockcroft and Davis, 2006).
Airway hyperresponsiveness can be deﬁned as an increase in
the ease and degree of airway narrowing in response to broncho-
constrictor stimuli in vivo. According to Alvarez-Puebla et al.
(2001), the development of an EAR in asthmatic patients is possibly
related to the degree of baseline bronchial hyperresponsiveness to
methacholine. The higher the provocative dose of methacholine
that produced >20% decrease in forced expiratory volume in 1 s
below the post-diluent value (PD20FEV1), the higher was the
threshold dose of allergen required to achieve the same effect. In
the present study, airway responsiveness to inhaled carbachol
was assessed by BWBP before entry into the initial inhalationchallenge-test period, but no relationship was found between pro-
vocative doses of allergen and carbachol (data not shown), which
suggested that the degree of baseline bronchial responsiveness as
measured by carbachol challenge was not expected to be a contrib-
utory factor towards the airway response to allergen in the present
model.
In humans, the degree of cutaneous allergic reactivity to aller-
gen, evaluated by the skin-prick test, is known to correlate well
with circulating levels of allergen-speciﬁc IgE in the serum, and
these levels have shown high capability to predict airway respon-
siveness to allergen (Bryant et al., 1975; Bryant and Burns, 1976).
In this study, we did not determine the degree of allergic sensiti-
sation (evaluated by intradermal skin testing in small animals or
by serum-speciﬁc IgE levels), although this could have been helpful
to distinguish the high- from low-responders among the AS-sensi-
tised cats.
The application of BWBP as a non-invasive pulmonary function
test and the use of its derived parameter, Penh, as a surrogate for
conventional measurements (i.e. respiratory mechanics) of airway
resistance have been severely criticised (Mitzner and Tankersley,
2003; Bates et al., 2004; Adler et al., 2004; Lundblad et al., 2007).
The pressure signal from the breathing of an animal in the plethys-
mographic box reﬂects both the effects of gas conditioning (heat-
ing and humidiﬁcation during inspiration versus cooling and
drying during expiration) and the effects of airway resistance on
alveolar pressure gradients that promote gas expansion during
inspiration and compression during expiration. According to some
investigators, pressure changes in a single-chamber BWB plethys-
mograph are essentially dependent upon gas conditioning and
therefore, Penh, which is based on the box pressure during expira-
tion, cannot be assumed as a reliable estimator of bronchoconstric-
tion but, at best, as a function of the ventilatory timing (e.g.
respiratory frequency) (Mitzner and Tankersley, 2003; Schwarze
et al., 2005: author reply). In the present study, no signiﬁcant cor-
relations (P > 0.05) were found between Penh and respiratory rate
(data not shown), in agreement with earlier experiments per-
formed in mice (Hamelmann et al., 1997). In contrast, clinical signs
compatible with bronchoconstriction (expiratory dyspnoea, cough-
ing and wheezes) broadly paralleled the time course of Penh.
Although the validity of Penh as a surrogate for lung resistance
has still to be proven in cats under varying respiratory conditions,
these ﬁndings along with others (Rozanski and Hoffman, 1999)
tended to indicate that the parameter Penh was well suited to as-
sess airﬂow limitation in cats with experimentally induced or nat-
urally occurring bronchospasm.
We believe this is the ﬁrst study to examine SAL, IB and the
combination SAL/IB delivered through pMDI for reversing
allergen-induced bronchospasm in cats. Neither bronchodilator
substantially improved lung function, as evidenced by AUC0–60,
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ated AS-elicited changes in Penh averaged over the 120 min obser-
vation period (AUC0–120), no such effects were noted over the ﬁrst
60 min (AUC0–60), when clinical status and lung function are sup-
posed to be most altered (see Initial inhalation challenge-test per-
iod). This may be unsatisfactory from a clinical standpoint. In line
with these negative ﬁndings are the observations in the recent lit-
erature that regular nebulisation of SAL in experimentally asth-
matic cats did not lessen the severity of symptoms the animals
displayed immediately after delivery of allergen (Reinero et al.,
2009).
Our results contrast sharply with those of a previous study con-
ducted by our group, in which inhalation of either SAL, IB or their
synergistic combination successfully prevented carbachol-induced
bronchoconstriction in healthy cats (Leemans et al., 2009). It is
conceivable that discrepancies between both studies may be re-
lated to methodological issues for the following reasons: Firstly,
the fact that inhalation of the bronchodilators was preventive in
the former study and curative in the latter could suggest differen-
tial drug exposure. Considering the approach implemented in the
current study, AS-related changes in airway calibre were thought
to reduce aerosol lung deposition, thereby increasing the likeli-
hood of poor response to inhaled bronchodilators. Secondly, carba-
chol has a bronchoconstrictor effect by acting directly on the
airway smooth muscle, whereas an allergen is an indirect stimulus
acting through the release of a number of mediators, which may
cause airway narrowing by mechanisms other than by airway
smooth-muscle contraction. Presumably the cats showed persis-
tent airway obstruction in spite of inhaling bronchodilators be-
cause of moderate to severe bronchial wall oedema and possibly
airway mucus plugging.
The inhaled bronchodilators tested in this study did not affect
measures of airﬂow limitation as much as expected from the re-
sults of preliminary clinical studies using BWBP as pulmonary
function testing (Rozanski and Hoffman, 1999; Hirt and Dederichs,
2001). In cats with diagnosed asthma, BWBP derived parameters
(Penh, Pause) effectively quantiﬁed both lower airway obstruction
and its reversal by treatment with SAL through pMDI (Rozanski
and Hoffman, 1999) or nebulised terbutaline (Hirt and Dederichs,
2001). However, there were no untreated asthmatic cats as con-
trols and no details on standardised intervals between drug admin-
istration and plethysmographic records, so these studies may have
missed the spontaneous recovery from the acute respiratory dis-
tress, which was critical in our model of allergic asthma. Therefore,
any comparisons with clinical data should be interpreted with cau-
tion until randomised controlled clinical trials are performed in pet
cats with asthma.
Administration of unsuitable drug doses may also have contrib-
uted to the apparent lack of activity of inhaled bronchodilators,
particularly when the airways are obstructed since penetration of
inhaled particles will be impaired. In this study, the choice of drug
dosage was based on recent recommendations for the prophylactic
use of inhaled bronchodilators in cats (Leemans et al., 2009).
Therefore, doses of bronchodilators higher than those recom-
mended may be needed to achieve effects reported from previous
pre-clinical and clinical trials (Rozanski and Hoffman, 1999; Hirt
and Dederichs, 2001; Leemans et al., 2009). It may be that be-
tween-group variability in AS-elicited changes in Penh led to
biased estimation of bronchodilators’ efﬁcacy. Nevertheless, statis-
tical analyses did not detect any signiﬁcant differences between
study groups (untreated, SAL, IB, SAL/IB) for response to allergenic
stimulation. This may be due to the study being underpowered
(P < 0.8), particularly when considering the small numbers of
experimental subjects. It should also be noted that a sustained
bronchoconstriction would have permitted more accurate assess-
ment of drug efﬁcacy in the present model.Conclusions
Established on the basis of AS sensitisation and inhalation, the
current feline model of allergen-induced bronchoconstriction of-
fers a standardised and repeatable approach for assessment of
bronchodilating drugs. Unexpectedly, inhaled SAL and IB, used as
single agents or for their combined therapeutic effect, did not sub-
stantially reverse the allergen-induced bronchospasms in AS-sen-
sitised cats. Research on cats with experimentally induced or
naturally occurring bronchospasm on a larger scale is required to
further explore ideal dosages and optimal dosing frequency of cur-
rently available inhaled bronchodilators or to look for more effec-
tive ways to administer suitable drugs to the respiratory system.
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